Mobile Health: Use and Regulation of Social Media, Mobile Apps, and Software
Sunday 28 October,
10:30 am-12:00 pm
| Room 6B
Within the span of a few years, the technology underpinning electronic interactions has been altered radically altered social media, body-worn sensors, smartphones with downloadable apps and software functionality delivered from cloud platforms. The healthcare industry, particularly those companies that manufacture FDA-regulated technologies used in healthcare, are not immune from the shift toward mobile access and social networks dominating electronic interactions with patients, providers, partners and government. This session will provide an overview of the regulatory impact of this changing landscape, from social media involvement in clinical trials to mobile medical apps. Insights from speakers with backgrounds at FDA and MHRA will enable attendees to obtain the latest information on current policy applications and future regulatory trends in response to the widespread adoption of these technologies by consumers in every aspect of their lives, including interactions with the healthcare system.
After this session, participants should be able to:
- Discuss how the changing
mobile health landscape will impact regulatory.
current policy applications and future trends in the US and EU.
||Colleen Hittle, RAC, president and CEO, Anson Group
Neil Ebenezer, PhD, head of New and Emerging Technologies, Devices Division, MHRA
Bakul Patel, policy advisor,
Peter Pitts, president and
co-founder, Center for Medicine in the Public Interest
Peter Pitts is president of the Center for Medicine in the Public Interest. He is a Special Government Employee (SGE) consultant to FDA’s Risk Communications Advisory Committee where he is advising the agency on regulatory issues in the sphere of social media. Previously, Pitts was FDA’s associate commissioner for external relations, serving as senior communications and policy adviser to the commissioner. He supervised FDA's Office of Public Affairs, Office of the Ombudsman, Office of Special Health Issues, Office of Executive Secretariat, and Advisory Committee Oversight and Management. . In 2010, he was named by Modern Healthcare magazine as one of the 300 “most powerful people in American healthcare.” His comments and commentaries on healthcare policy issues regularly appear in national and international media. His book, Become Strategic or Die, is widely recognized as a cutting edge study of how leadership, in order to be successful over the long term, must be combined with strategic vision and ethical practice. He is the editor of Coincidence or Crisis, a discussion of global prescription medicine counterfeiting, and Physician Disempowerment: A Transatlantic Malaise. He has served as an adjunct professor at Indiana University’s School of Public and Environmental Affairs and Butler University.